Grant of AESOP Options and PDMR Dealing
Updated : 14:44
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Grant of AESOP Options, PDMR Dealing
Cambridge, UK, 17 November 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, announces that on 16 November 2022, it granted a total of 323,500 options under the Company's All Employee Share Ownership Plan ("AESOP Options") over new ordinary shares of 0.1 pence each in the Company ("Ordinary Shares").
The AESOP Options vest after 36 months and are exercisable at £2.45 per share being the closing market price of an Ordinary Share on the day preceding the date of grant. The AESOP Options are subject to continuous employment, vest in accordance with the vesting term notified to the option holder and are exercisable until the tenth anniversary of the date of grant, after which date the option will lapse.
The following 159,000 AESOP Options were granted to persons discharging managerial responsibilities ("PDMR"):
PDMR | Position/status | Number of AESOP options granted on 16 November 2022 | Total number of AESOP options held |
Shafiq Choudhary | Managing Director, Tetris Pharma | 40,000 | 40,000 |
David Gerring | VP Development | 40,000 | 70,000 |
Sarah Howell | Chief Executive Officer | 33,000 | 133,000 |
Jan Jezek | Chief Scientific Officer | 13,000 | 53,000 |
Fiona Lawrence | VP Clinical Development and Reg. Affairs | 10,000 | 40,000 |
Susan Lowther | Chief Financial Officer | 23,000 | 93,000 |
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.
For further information, please contact:
Arecor Therapeutics plc
| |
Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com
|
Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: info@arecor.com
|
| |
Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com |
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
Consilium Strategic Communications | |
Chris Gardner, David Daley, Angela Gray | Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat ™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: | Shafiq Choudhary | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Managing Director, Tetris Pharma | ||||
b) | Initial notification/Amendment: | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Arecor Therapeutics plc | ||||
b) | LEI: | 98450093D12I3A8DDD58 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||
b) | Nature of the transaction: | Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: |
40,000 N/A | ||||
e) | Date of the transaction: | 16 November 2022 | ||||
f) | Place of the transaction: | Outside of a trading venue | ||||
Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: | David Gerring | ||||
2. | Reason for the notification | |||||
a) | Position/status: | VP Development | ||||
b) | Initial notification/Amendment: | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Arecor Therapeutics plc | ||||
b) | LEI: | 98450093D12I3A8DDD58 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||
b) | Nature of the transaction: | Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: |
40,000 N/A | ||||
e) | Date of the transaction: | 16 November 2022 | ||||
f) | Place of the transaction: | Outside of a trading venue | ||||
Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: | Sarah Howell | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Executive Officer | ||||
b) | Initial notification/Amendment: | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Arecor Therapeutics plc | ||||
b) | LEI: | 98450093D12I3A8DDD58 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||
b) | Nature of the transaction: | Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: |
33,000 N/A | ||||
e) | Date of the transaction: | 16 November 2022 | ||||
f) | Place of the transaction: | Outside of a trading venue | ||||
Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: | Jan Jezek | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Scientific Officer | ||||
b) | Initial notification/Amendment: | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Arecor Therapeutics plc | ||||
b) | LEI: | 98450093D12I3A8DDD58 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||
b) | Nature of the transaction: | Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: |
13,000 N/A | ||||
e) | Date of the transaction: | 16 November 2022 | ||||
f) | Place of the transaction: | Outside of a trading venue | ||||
Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: | Fiona Lawrence | ||||
2. | Reason for the notification | |||||
a) | Position/status: | VP Clinical Development and Reg. Affairs | ||||
b) | Initial notification/Amendment: | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Arecor Therapeutics plc | ||||
b) | LEI: | 98450093D12I3A8DDD58 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||
b) | Nature of the transaction: | Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: |
10,000 N/A | ||||
e) | Date of the transaction: | 16 November 2022 | ||||
f) | Place of the transaction: | Outside of a trading venue | ||||
Details of the person discharging managerial responsibilities/person closely associated | ||||||
a) | Name: | Susan Lowther | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Financial Officer | ||||
b) | Initial notification/Amendment: | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Arecor Therapeutics plc | ||||
b) | LEI: | 98450093D12I3A8DDD58 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary shares of 1 pence each GB00BMWLM973 | ||||
b) | Nature of the transaction: | Grant of options over ordinary shares | ||||
c) | Price(s) and volume(s): |
| ||||
d) | Aggregated information: · Aggregated volume: · Price: |
23,000 N/A | ||||
e) | Date of the transaction: | 16 November 2022 | ||||
f) | Place of the transaction: | Outside of a trading venue | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.